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Table 6: Summary of in vitro permeation skin studies conducted with caffeine formulations  
Formulation Tissue Author(s) Caffeine concentration / 
amount applied  
Permeation parameter reported  
Ointment bases  Human Zesch et al. (1979) 0.1 %, 4.3 g /cm2 SC penetration:  0.63 – 2.18 g/cm2 
Petrolatum, ethylene glycol gels, aqueous 
gels  
Human Bronaugh and Franz (1986) 0.5 – 60 g /cm2 kp : 2.1 – 7.2 x 10
-4 cm/h 
Ethoxylated amines  Human  Hadgraft et al. (1986) 0.2 %  kp: 2.5 – 4.9 x 10
-3 cm/h 
OA, LA Human Green et al. (1988) 0.2 %, 1.1 g /cm2 kp: 3.0– 4.5 x 10
-3 cm/h 
Water, PGDP, Labrafil M 1944, Labrasol®, 
PG, Transcutol™, PG/PGDP  
Human  Bonina et al. (1993) 0.2 – 2.8%, 0.3 – 3.7 mg/cm2 J: 0.3 – 2.3 g/cm2/h 
PG, PG/water, PG/ethanol, PG/OA, 
PG/water/OA, ethanol/water/OA, 
PG/Azone™, PG/menthone, PG/limonene, 
PG/cineole 
Human  Thakur et al. (2007) 0.8– 2.8%, 1.1 – 3.7 mg/cm2 J: 0 – 585 ± 44 g/cm2/h 
Water, PG/ethanol/water, 1,2-
pentanediol/Water, PG/water, 
ethanol/water 
Porcine  Duracher et al. (2009) 2 %, 0.2 mg/cm2 kp: 1.7 – 7.7 x 10
-4 cm/h 
Cumulative permeation:  32.4 – 179.7 
g/cm2 
Cationic “gemini” surfactants/PG Porcine  Silva et al. (2013)  1.5 %, 7 mg/cm2 J: 6.1 – 10.9 g/cm2/h 
Cumulative permeation: 127.9 – 226.9 
g/cm2 
Spilanthol/ethanol/water Human De Spiegeleer et al. (2013) 5.4%, 42 mg/cm2 Cumulative permeation: ~300 – 1000 
g/cm2 
Phytoceramides/ethanol/water Human  Veryser eta l. (2015) 5.4%, 42 mg/cm2 kp: 2.1 – 7.0 x 10
-4 cm/h 
J: 10..9 – 35.4 g/cm2/h 
Emulsions (O/W) Human  Bonina et al. (1992) 0.1 %, 133 g/cm2 kp: 1.5 – 2.9 x 10
-3 cm/h 
J: 0.2 -1.6 g/cm2/h 
Emulsions (O/W, W/O/W) Human  Doucet et al. (1998) 1 %, 2.6 mg/cm2 kp: 2.4 – 6.0 x 10
-4 cm/h 
J: 2.4 – 6 g/cm2/h 
Emulsions (O/W, W/O), hydrogel Human Dreher et al. (2002)  1 %, 0.1 mg/cm2 Percentage permeation: 15 – 20% 
Emulsion (O/W), microemulsion,hydrogel Porcine  Bolzinger et al. (2007)  0.8 %, 3.2 mg/cm2 kp: 2.0 – 3.6 x 10
-3 cm/h 
J: 15.6 – 28.8 g/cm2/h 
Table(s)
Emulsion (W/O), Pickering emulsion 
(W/O) 
Porcine  Frelichowska et al. (2009) 0.8 %, 3 mg/cm2 kp: 1.0 – 3.0 x 10
-3 cm/h 
J: 10– 25 g/cm2/h 
Microemulsions (O/W, W/O, 
bicontinuous) 
Porcine Naoui et al. (2011) 0.8 %,3 mg/cm2 kp: 4.0 – 12.0 x 10
-3 cm/h 
J: 35 – 99 g/cm2/h 
Microemulsions (O/W, W/O, 
bicontinuous) 
Porcine Zhang and Michniak-Kohn 
(2011) 
1 %  J: 5.1 – 11.6 g/cm2/h 
Cumulative permeation: 91.8 – 237.8 
g/cm2 
Microemulsions (O/W,  O/W gel) Porcine Sintov and Greenberg 
(2014) 
1 %, 2.8 mg/cm2 kp: 1.3 – 1.5 x 10
-3 cm/h  
Cumulative permeation: 264.5 – 322.7 
g/cm2 
Nanoparticles (Starch derivatives) Human Santander-Ortega et al. 
(2010) 
- Cumulative permeation:  <0.2 g/cm2 
Nanoparticles (Silica composites) Porcine Pilloni et al. (2013) 3 %, 4.7 – 9.4 mg/cm2 kp: 2.0 – 2.2 x 1
0-4 cm/h 
J: 6.0 – 6.9 g/cm2/h 
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Abstract  15 
 Caffeine is administered topically and transdermally for a variety of  pharmaceutical and 16 
cosmetic applications and it is also used as a model hydrophilic compound in dermal risk assessment 17 
studies. This review considers the physicochemical and permeation properties of caffeine with 18 
reference to its delivery to and through the skin. Since it has been used as a model compound the 19 
findings have implications for the delivery of many hydrophilic compounds having similar properties.  20 
Various passive and active formulation strategies to promote enhanced skin permeation of caffeine 21 
are considered. Models to study percutaneous caffeine penetration are also discussed in detail.  22 
 23 
Key words: Caffeine, topical, transdermal, formulation, permeation   24 
  25 
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1. Introduction 26 
 Caffeine (1,3,7-trimethylpurine-2,6-dione) is a methyl xanthine alkaloid which is consumed 27 
as a beverage, administered as a medicine or applied for cosmetic purposes (Figure 1). Caffeine is 28 
also employed as a model hydrophilic compound in skin toxicology; dermal absorption of such 29 
“marker” compounds is used for risk assessment of exposure to hazardous substances in man 30 
(OECD, 2004). Caffeine is recommended as a test substance by the OECD because it has been studied 31 
extensively in vitro and in vivo. Although coffee and other caffeine containing drinks, such as tea, 32 
have been consumed at least since the fifteenth century the molecule itself was not isolated until 33 
1820 (Anft, 1955). This article focusses on caffeine interactions with the skin with an emphasis on 34 
topical delivery strategies; systemic delivery of caffeine is also possible in certain cases. The major 35 
route for actives to permeate through the skin is via the lipid content of the outermost layer (Menon 36 
et al., 2012), the stratum corneum (SC). However, caffeine does not possess the properties of an 37 
ideal skin penetrant as it is a hydrophilic material with a Log P of -0.07 (Table 1). Caffeine also 38 
exhibits unusual solubility behaviour in non-aqueous solvents (Bustamante et al., 2002) and forms 39 
aggregates in aqueous solutions (Guttmann and Higuchi, 1957; Cesaro et al., 1976). The various 40 
formulation approaches which have been employed to date to enhance skin penetration of caffeine 41 
will be reviewed. Only studies on human and porcine skin are considered as other models are not 42 
reliable predictors of skin penetration in man.  43 
 44 
Table 1. Physicochemical properties of caffeine  45 
Molecular Weight* 194.2 
Log P* -0.07  
Solubility* 1 in 46 of water, 1 in 1.5 of boiling water  
Solubility parameter** 31 MPa½ 
Melting point* 238°C 
pKa * 14 (25°C), 10.4 (40°C) 
*Moffat et al. 2004 46 
**Bustamante et al., 2002 47 
 48 
2. Pharmacology, pharmacokinetics and metabolism  49 
Caffeine inhibits the phosphodiesterase enzyme and has an antagonistic effect on central 50 
adenosine receptors. It is a stimulant of the Central Nervous System and may produce wakefulness 51 
and heightened mental activity. The molecule also increases rate and depth of respiration but it is a 52 
weaker bronchodilator than theophylline (Parfitt and Martindale, 1999). Caffeine has been 53 
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investigated for its neuroprotective effects in dementia (Ritchie et al., 2007) as well as its potential 54 
as an aid to recognise hypoglycaemic symptoms in diabetic patients (Debrah et al., 1996; Watson et 55 
al., 2000). The major advantages claimed for use of caffeine in topical cosmetic products are that it 56 
(i) prevents excessive fat accumulation in skin, (ii) promotes lymphatic drainage and (iii) protects skin 57 
from photodamage. Scientific evidence for many of these proposed benefits is lacking and most 58 
studies in the literature are based on cell culture or mouse models (Herman and Herman, 2013). The 59 
efficacy of caffeine in the management of gynoid lipodystrophy (cellulite) via proposed adipocyte 60 
lipolysis and increased cyclic adenosine monophosphate (cAMP) is controversial. The applications of 61 
caffeine in the management of this condition have been reviewed by Herman and Herman (2013). 62 
The authors describe in detail potential roles for caffeine in lipolysis including effects on 63 
catecholamine secretion, cAMP levels, lipase activity, PDE inhibition and lymphatic drainage. 64 
Although caffeine has been shown in vitro to promote follicular proliferation evidence for this effect 65 
in vivo has not been reported(Fischer et al., 2007).  66 
 When administered orally, the bioavailability of caffeine is ~100% with values for plasma 67 
half-life, volume of distribution and clearance reported respectively as 2 -10 h, 0.5 L/kg and 1 – 2 68 
mL/min/kg (Moffat et al., 2004). The extent to which the molecule binds to plasma proteins is ~35% 69 
(Blanchard, 1982). For treatment of neonatal apnoea of prematurity the recommended dose is 5 – 70 
20 mg/kg caffeine (as the citrate) administered orally or intravenously. The recommended oral dose 71 
of caffeine for mild stimulant purposes is 50 – 200 mg daily (Parfitt and Martindale, 1999). Following 72 
oral administration, caffeine may be subject to metabolism by N-demethylation, acetylation and 73 
oxidation; approximately 1% of the molecule is excreted unchanged. There is no evidence, to date, 74 
that caffeine undergoes appreciable metabolism following application to skin.  Poisonings and 75 
fatalities have followed ingestion of large oral doses of caffeine but no toxic or skin reactions have 76 
been reported following dermal exposure in healthy patients (Moffat et al., 2004).  77 
 78 
3. Skin permeation of caffeine  79 
This section reviews percutaneous penetration of caffeine from simple aqueous solutions and 80 
solvents. The influence of application site, age, occlusion, tissue preparation for in vitro studies 81 
transport in hair follicles and lateral diffusion properties on caffeine skin penetration is also 82 
examined. Strategies to promote caffeine permeation based on chemical or physical enhancement 83 
of skin delivery or other means are discussed in Sections 4 and 5.  84 
 85 
3.1 Influence of anatomic site  86 
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Feldmann and Maibach (1970) investigated the permeation of caffeine in human subjects. A 87 
dose of 4 g/cm2 of CAF was applied in acetone to the ventral forearm over a total area of 13 cm2. 88 
Absorption values of ~50% were reported following urinary collection over 5 days. Franz (1975) 89 
investigated caffeine permeation in vitro and reported median percentage absorption of 9% of 90 
caffeine from a finite dose application. In a later report by Franz (1978) the values for caffeine 91 
absorption in vitro and in vivo, respectively were reported as 24.1 ± 7.8% and 22.1 ± 15.8%. The 92 
differences in the earlier values for in vivo caffeine absorption were attributed to the correction 93 
used for urinary excretion and the duration of sample collection. Rougier and co-workers (1987) 94 
investigated the skin permeation of caffeine as a function of other anatomic sites in human subjects. 95 
A solution of caffeine in ethylene glycol, Triton X-100 and water was applied to the arm, abdomen, 96 
post-auricular region or forehead. After 30 min contact the sites were washed with ethanol/water 97 
followed by a rinse with water and then dried. Total amounts of caffeine penetrated were ranked as 98 
follows: forehead>arm>post auricular region>abdomen. This is consistent with recent data reported 99 
by Machado et al. (2010); these workers calculated effective pathlengths for water diffusion as a 100 
function of anatomic site.  101 
 102 
3.2 Influence of age 103 
The influence of aging on skin permeation of caffeine was examined by Roskos et al. (1989). A 104 
finite dose (4 g/2.5 cm2) of caffeine in acetone was applied to the forearms of young (22-40 years) 105 
and old (65-86 years) subjects. A protective patch (non-occlusive) was then applied over the 106 
application site for 24 h followed by washing of the skin and collection of urinary samples. The dose 107 
recovered was 32.1 ± 4.2% for the young group while the corresponding value for the old group was 108 
61.8 ± 5.4%. This was a relatively small study with 5 volunteers for the young group and 7 for the 109 
older group and data were expressed as mean values with standard error of the mean. As sebaceous 110 
gland activity and lipid content of skin changes with age (Pochi et al., 1979) the authors suggested 111 
that this might explain the diminished amounts of caffeine absorption in the older subjects. 112 
However, changes in corneocyte size and skin hydration with age are also likely to influence caffeine 113 
permeation with age. The barrier function of skin is not fully developed in new-born infants 114 
particularly if they are immature. Amato et al. (1991, 1992) reported transdermal delivery of caffeine 115 
in preterm infants for the management of apnoea. Caffeine (as the citrate salt) was applied twice 116 
daily in a gel formulation; total daily doses were 20 mg for babies with birth weights  < 1000 g and 15 117 
mg for babies with birth weights > 1000 g. Therapeutic levels were considered to be 25 – 100 mol/L 118 
and were achieved within 48 h of the first application of the gel. Transdermal delivery of caffeine is 119 
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attractive in this case as oral absorption of drugs in low birth weight infants is erratic, unpredictable 120 
and sometimes not possible because of gastrointestinal disease (Evans and Rutter, 1986).  121 
 122 
3.3 Influence of occlusion  123 
Treffel et al. (1992) investigated the effects of occlusion on the in vitro skin permeation of 124 
caffeine. The dose of caffeine applied was 2.6 g/cm2 in an acetone solution (160 g/mL). 125 
Specialised diffusion cells with a completely closed donor compartment were used for the occlusion 126 
study and conventional Franz cells were used for the corresponding unoccluded study. Cumulative 127 
amounts of caffeine permeated after 24 h were of the order of 1 g/cm2 and were not significantly 128 
different for occlusion compared with no occlusion.  129 
 130 
3.4 In vitro studies with human skin and porcine tissue  131 
A multi-laboratory study investigated caffeine permeation in vitro under finite dose 132 
conditions (van de Sandt et al., 2004). Caffeine was applied as a 0.4 %w/v solution in ethanol:water 133 
(1:1) and dosed at 25 l/cm2 to human skin samples. Maximum flux values and percentage 134 
permeated for caffeine were 2.24 ± 1.43 g/cm2/h and 24.5 ± 11.6% respectively. Cumulative 135 
amounts of caffeine which had permeated by the end of the experiment were not reported.  136 
Schreiber et al. (2005) reported the in vitro permeation of caffeine in human and porcine 137 
skin. Infinite doses of caffeine were applied (285 l/cm2 of a 1% w/v solution in phosphate buffered 138 
saline) to the donor compartments of Franz cells and permeation experiments were conducted up to 139 
6 h. Cumulative amounts of caffeine permeated were ~150 g/cm2 for dermatomed, cryopreserved, 140 
porcine abdominal skin and ~10 g/cm2 for heat separated human epidermis. No differences in 141 
caffeine permeation were observed for full thickness human skin compared with heat separated 142 
human skin. Unfortunately, the authors did not conduct the corresponding finite dose study. Skin 143 
penetration of caffeine in vitro using heat separated or dermatomed human skin was investigated by 144 
Atrux-Tallau et al. (2007). The dose of caffeine applied was 128 g/cm2 as an aqueous solution. 145 
Values for cumulative amounts of caffeine permeated were ~30 g/cm2 (~23% of the applied dose) 146 
for heat-separated skin which were not significantly different for dermatomed tissue. This is to be 147 
expected as the hydrophilic nature of caffeine would result in faster permeation through dermal 148 
tissue. 149 
 150 
3.5 Caffeine transport through hair follicles 151 
Otberg et al. (2008) investigated the transport of caffeine through hair follicles. A solution of 152 
caffeine in ethanol and propylene glycol (PG) was applied to the chest of male volunteers; caffeine 153 
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was dosed at 10 g/cm2 over 25 cm2. Blood samples were taken up to 72 h following application of 154 
the formulation. Following a 7-day interval hair follicles on the same sites were blocked using a 155 
varnish/wax mixture. The caffeine formulation was then applied and blood samples collected as for 156 
the first study. Serum caffeine values for open follicles were reported as 3.75 ng/mL, 5 min after 157 
application of the formulation, but caffeine could not be detected following application to the closed 158 
follicle sites until 20 min after application. Caffeine values were generally lower for the sites with 159 
closed follicles compared with the site with unblocked follicles. In a later study Trauer et al. (2009) 160 
investigated the effects of blocking hair follicles on caffeine permeation in vitro using Franz cells.  161 
Excised female breast skin was used and the same formulation used in the earlier in vivo study was 162 
applied but the dose of caffeine was five-fold higher because of limitations with the analytical 163 
method used. Permeation studies were conducted for 24 h with caffeine detection in the receptor 164 
compartment after 2 h. Significantly higher amounts of caffeine (p<0.05) were observed for skin with 165 
unblocked follicles (0.39 %) compared with the closed follicular skin (0.09 %). At 24 h the amount of 166 
caffeine recovered from the control skin was ~17% and for the skin with blocked follicles the 167 
recovery was ~7%. These data point to an important role for the follicular pathway in caffeine skin 168 
permeation but further studies are required to confirm this.  169 
 170 
3.6 Influence of skin washing  171 
Nielsen (2010) investigated the effects of skin washing on caffeine permeation in vitro. 172 
Solutions of caffeine (4 mg/mL) were applied at a dose of 50 L/cm2 to human skin mounted in 173 
diffusion cells. At 6 h the skin surface and donor compartment were gently cleaned using soap of 174 
neutral pH and a cotton swab followed by two rinses with isotonic water. Following drying, 175 
permeation continued and samples were taken for all cells up to 42 h. At the end of the experiment 176 
the amounts of caffeine permeated were 24 % for the control group and 8 % for the cells which had 177 
been washed. This would suggest that a significant amount of caffeine resided on the skin and was 178 
washed from the surface. 179 
 180 
3.7 Lateral skin diffusion  181 
Gee et al. (2012) used a novel tape stripping technique to investigate the lateral diffusion of 182 
caffeine both in vitro and in vivo. Dermatomed human abdominal skin was employed for in vitro 183 
studies with 1.8 l of caffeine (0.8 % w/v) being applied to the donor compartment of Franz cells. 184 
Permeation studies were conducted up to 6 h. For in vivo studies a solution of caffeine in ethanol 185 
(1.8 l, 0.8 % w/v) was applied to an area of 0.5 cm2 on the volar forearm of 8 volunteers (4 males, 4 186 
females). After 3 min, 3 h and 6 h, tape perforated into concentric circles was used to strip the area 187 
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of application as well as adjacent areas. A total of 10 tape strips was taken for each site from which 188 
drug and protein content were determined. Lateral diffusion and limited skin penetration was 189 
observed for caffeine at 3 min compared with other drugs studied (ibuprofen and hydrocortisone). 190 
The authors suggested that the comparatively wider lateral diffusion observed for caffeine might 191 
reflect the presence of a moisture film at the skin surface which would aid dissolution and spreading 192 
of the molecule.  193 
 194 
4. Formulation strategies for delivery of caffeine to the skin  195 
4.1 Ointments and gels  196 
 One of the earliest investigations to compare the influence of vehicle on caffeine delivery 197 
was reported by Zesch et al. (1979). Four ointment bases containing 0.1% w/w caffeine were 198 
evaluated namely Vaseline™, aqueous wool wax alcohol ointment (water-in-oil emulsion), aqueous 199 
hydrophilic ointment (oil-in-water emulsion) and a polyethylene glycol ointment.  For in vitro studies 200 
30 mg of ointment was applied to human skin over a 7 cm2 area. One preparation (aqueous wool 201 
wax alcohol ointment) was evaluated further in vivo with 100 mg of ointment being applied to a 28 202 
cm2 site. Following application ointments were rubbed in for 90 s to ensure uniform distribution and 203 
the time allowed for penetration was 10, 30, 100, 300 and 1000 min. At the end of the permeation 204 
period skin biopsies and tape stripping were conducted for both sets of experiments. The best 205 
penetration (2.18 g/cm2) into the SC in vitro was observed for the aqueous woolwax alcohol 206 
ointment with the poorest uptake observed for the polyethylene glycol ointment (0.63 g/cm2). 207 
Similar permeation into the SC in vitro was observed for Vaseline™ and the aqueous hydrophilic 208 
ointment despite the differences in their composition. However for the epidermis in vitro data at 209 
100 min indicated that the aqueous hydrophilic ointment (oil-in-water emulsion) delivered the 210 
greatest amount of caffeine with the poorest delivery from the aqueous woolwax alcohol ointment. 211 
Much lower caffeine values for SC and epidermis (0.31 and 0.05 g/cm2 respectively) were observed 212 
in vivo compared with the in vitro results which were attributed to clearance of caffeine by the skin 213 
vasculature.  214 
 Bronaugh and Franz (1986) evaluated caffeine permeation from petrolatum, gels containing 215 
ethylene glycol and simple aqueous gels in human skin, in vitro and in vivo. Doses applied in vitro 216 
were 25 mg/cm2 or greater with caffeine amounts varying from 0.5 – 60 g/cm2 depending on the 217 
vehicle studied. Maximum permeation was observed for the petrolatum vehicles followed by the 218 
ethylene glycol gels with lowest permeation from the aqueous gel. This trend was consistent with 219 
the degree of saturation of caffeine in the respective vehicles. Results for in vivo absorption were in 220 
general agreement with the in vitro studies.  221 
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 222 
4.2 Penetration enhancers  223 
 Penetration enhancers are chemicals which are proposed to modify transiently the solubility 224 
of an active in the skin and/or promote enhanced diffusion of the active (Lane, 2013). Hadgraft et al. 225 
(1986) investigated the effects of an ethoxylated amine on caffeine penetration in vitro. Pre-226 
treatment of human skin with either 10 or 100 mM of bis-(2-hydroxyethyl)oleylamine in ethanol 227 
increased the permeability coefficient of caffeine by a factor of 40 compared with ethanol alone. 228 
However these studies were conducted under infinite dose conditions therefore permeation 229 
enhancement is likely over-estimated compared with the amounts of caffeine that are typically 230 
applied in vivo. Green et al. (1988) assessed the effects of oleic acid (OA) and lauric acid (LA) on the 231 
skin penetration of caffeine. Human skin mounted in Franz cells was pre-treated with a solution of 232 
the fatty acid in ethanol for a period of 2 h. Permeation of caffeine was increased for both fatty acids 233 
but as for the previous studies experiments were conducted under infinite dose conditions. The 234 
authors also noted that caffeine did not form ion pairs with the fatty acids.  235 
Suspensions of caffeine in a range of solvent enhancers have been evaluated by Bonina et al. 236 
(1993). Permeations experiments were conducted with human skin over 24 h; flux values reported 237 
are shown in Table 2.  238 
 239 
Table 2. Solubility and skin flux of caffeine from a range of vehicles (Adapted from Bonina et al., 240 
1993) 241 
Vehicle Solubility* 
(mg/mL) 
Flux  
g cm-2 h-1) 
Water 27.9 ± 1.7  0.72 ± 0.04 
Propylene glycol dipelargonate  1.9 ± 0.1  2.28 ± 0.35 
Labrafil M 1944  3.3±  0.4  1.16 ± 0.09 
Labrasol  12.0 ± 0.8  0.28 ± 0.06 
Propylene glycol 13.9 ± 1.2 0.70 ± 0.1 
Transcutol 14.1 ± 0.9 0.64 ± 0.2  
Propylene glycol / Propylene glycol 
dipelargonate   
13.9 ± 0.9 2.19 ± 0.17 
*Measured at 30°C for 48 – 72 h 242 
 243 
Compared with the flux values for the aqueous suspension, no enhancement of caffeine 244 
permeation was observed for Labrasol®, Transcutol® or PG. Improved transport was observed for 245 
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propylene glycol dipelargonate (PGDP), Labrafil® M 1944 and a mixture of PGDP and PG. Labrasol® is 246 
a mixture of ethoxylated C8 and C10 glycerides, glycerides and free polyethylene glycol (PEG), 247 
Transcutol® is a monomethyl ether and Labrafil® M 1944 consists of ethoxylated glycerides and 248 
glycerides. The superior effects of the PG / PGDP vehicle were attributed to the ability of PGDP to 249 
interact with intercellular skin lipids combined with the ability of PG to promote uptake of PGDP into 250 
the skin.  251 
 Four terpenes as well as oleic acid and Azone® were evaluated by Thakur et al (2007) for 252 
their ability to enhance delivery of caffeine to the skin. Enhancers were incorporated (5 % v/v) in 253 
saturated solutions of caffeine in PG; the control consisted of a saturated solution of caffeine in PG. 254 
OA was also evaluated in three other vehicles, namely PG:ethanol (33:67), PG:water (50:50) and 255 
water:ethanol (30:70). Formulations (100 L) were applied to dermatomed human skin samples 256 
mounted in Franz cells with an effective diffusion area of 0.64 cm2. Permeation experiments were 257 
conducted under occlusion for 24 h and results are summarised in Table 3. Maximal permeation was 258 
observed for the hydro-alcoholic vehicle containing OA consistent with synergistic effects on 259 
permeation. However, since infinite dose conditions were employed the data have limited 260 
applicability for finite dose conditions.  261 
 262 
Table 3. Solubility and flux values of caffeine for a range of vehicles (Adapted from Thakur et al., 263 
2007) 264 
Vehicle Enhancer  
 
Solubility 
(mg/mL) 
Flux  
(g/cm2/h) 
PG -  8.4 ±0.4 0.7 ±0.1 
PG OA  5% 15.2 ±0.6 40.3 ±5.1 
PG:Ethanol OA 5% 13.8± 0.8 75.0 ±14.0 
PG:Water OA 5% 19.4± 0.1 47.6 ±6.2 
Water:Ethanol OA 2% - 50.5 ±4.6 
Water:Ethanol OA 5% 28.2 ±0.1 162.7 ±38.7 
Water:Ethanol OA 10% - 585 ± 44  
PG Azone 5% 15.7 ±0.0 27.3 ±6.2 
PG Cineole 5% 17.3 ±1.1 7.0 ±4.8 
PG Limonene 5% 17.6 ±0.6 0 
PG Menthone 5% 17.2 ±0.4 2.5 ±1.4 
PG Terpineol 5% 18.9 ±1.0  2.4 ±1.0 
 265 
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 Duracher and co-workers (2009) investigated 1,2-pentanediol, ethanol and PG as 266 
penetration enhancers for caffeine using full thickness porcine skin. Formulations containing 2% 267 
caffeine were prepared as outlined in Table 4. For permeation studies 10 L of each vehicle was 268 
applied to porcine ear skin with a surface area of 0.95 cm2. Experiments were conducted for 24 h 269 
with occlusion of the donor compartment. Mass balance studies were also conducted by washing 270 
the surface of the skin, tape stripping to remove the SC as well as extraction of caffeine from the 271 
epidermis and dermis. The incorporation of small amounts of 1,2-pentanediol clearly promoted 272 
caffeine penetration compared with the aqueous vehicle. Approximately 32% and 65% of caffeine 273 
penetrated the skin for the vehicles containing respectively 2.5% and 5% of 1,2-pentanediol however 274 
the highest cumulative permeation was observed for a ternary ethanol:PG:water system. This 275 
probably reflects the synergistic effects of the enhancers in this formulation. A ternary system 276 
containing 1,2-pentanediol and ethanol would have been a useful comparator study and would 277 
allow investigation of any potential synergy betwen these enhancers.  278 
 279 
Table 4. Caffeine skin permeation for vehicles studied by Duracher et al. (2009) 280 
Vehicle Cumulative permeation at 24 h 
(g) 
Water 39.8 ±16.7 
PG:Ethanol:Water (25:25:48) 170.7 ±38.3 
1,2-pentanediol:Water (2.5:95.5) 68.7 ±17.1 
1,2-pentanediol:Water (5:93) 153.5 ±31.4 
PG:Water (5:93) 93.0 ±18.9 
Ethanol:Water (5:93) 30.8 ±3.7 
*Determined at 25 ±1°C over 24 h 281 
 282 
 A series of cationic ‘gemini’ surfactants were evaluated by Silva et al. (2013) for their effects 283 
on caffeine penetration. These molecules differ from conventional surfactants as they contain two 284 
hydrophilic tails and at least two hydrophobic tails linked covalently by a spacer group. The 285 
surfactants studied were dimethylene-1,2- bis(dodecyldimethylammonium bromide), 286 
hexamethylene-1,2-bis(dodecyldimethylammonium bromide) and decamethylene-1,2-287 
bis(dodecyldimethylammonium bromide). Solutions of surfactants were prepared in PG at a 288 
concentration of 0.16 M with the single chain surfactant dodecyltrimethylammonium bromide, 289 
Azone® and PG alone used for comparison. Dermatomed porcine tissue mounted in Franz cells was 290 
pre-treated with the various preparations for 1 h prior to application of 0.3 mL of a caffeine gel (1.5 291 
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% w/w) to the donor compartments (diffusional area 0.64 cm2). After 24 h two of the gemini 292 
surfactants as well as the single chain surfactant demonstrated a two-fold enhancement of caffeine 293 
permeation (8.2 – 10.9 g/cm2/h compared with no pre-treatment (4.5 g/cm2/h). As the studies 294 
were conducted under infinite dose conditions finite dose experiments may elucidate more clearly if 295 
these surfactants have real potential for topical delivery. A further issue is that such molecules 296 
typically have much lower critical micelle concentrations than conventional surfactants which may 297 
have implications for thermodynamic activity of the active.  298 
 Spilanthol, an N-alkylamide obtained from the Acmella plant species has recently been 299 
evaluated for its skin penetration enhancement properties with reference to caffeine (De Spiegeleer 300 
et al., 2013). A range of concentrations of the enhancer were incorporated in ethanol:water (50:50) 301 
solutions with caffeine (4.3 % w/v). Permeation experiments were conducted with dermatomed 302 
human skin in Franz cells and formulations were dosed at 500 l over 0.64 cm2. The maximum 303 
cumulative caffeine permeation (~650 g) was observed for solutions containing spilanthol 1% w/v 304 
which was significantly greater than that observed for the control solution (~150 g). For all 305 
concentrations of the enhancer studied most of the caffeine was deposited on the surface of the 306 
skin or in the epidermis. The very high permeation values reported are consistent with the large 307 
doses of caffeine applied (35 mg/cm2).  308 
 A new class of lipids containing hydrophobic oleyl chains and heterocyclic head groups was 309 
synthesised by Singh et al. (2013). The skin penetration enhancement properties with respect to 310 
caffeine were examined in vitro using human skin. All lipid formulations also contained Transcutol®.  311 
Although the authors claimed that permeation enhancement was observed for each of the lipids the 312 
influence of Transcutol® was not considered.  Information on the control formulations lacked 313 
sufficient detail and no permeation profiles were provided for any of the formulations.   314 
 Most recently Veryser et al (2015) have evaluated phytoceramides as potential skin 315 
penetration enhancers of caffeine. Ceramides consist of a sphingosine molecule linked to a fatty acid 316 
via an amide linkage; phytoceramides contain no unsaturated C4-C5 linkage and contain an additional 317 
hydroxyl group at C4. Formulations were prepared as reported in an earlier study (De Spiegeleer et 318 
al., 2013) with caffeine incorporated at 80% of its saturation solubility in ethanol:water (50:50) 319 
vehicles. Phytoceramides were incorporated at a concentration of 1% w/v and Azone® was used as a 320 
positive control. All formulations were evaluated in Franz cell studies with human skin; the dose 321 
applied was 500 l/0.64 cm2. After 24 h, cumulative permeation for a solution of caffeine alone was 322 
~150 g and maximum values for the phytoceramide formulations did not exceed ~400 g. 323 
Statistical analysis was not conducted to determine the significance of the permeation differences. 324 
In contrast the corresponding permeation value for Azone® was 1,609 g. Percentages of caffeine 325 
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permeated were 5.98 ± 97 % for the Azone® formulation and did not exceed 1.6 % for the 326 
phytoceramide preparations.  327 
 328 
4.3 Emulsions, microemulsions, Pickering emulsions  329 
 The effects of emulsion vehicles on caffeine skin penetration were investigated by Bonina 330 
and co-workers (1992). Formulations were prepared using an emulsion base consisting of glycerine, 331 
PEG-24 glyceryl stearate, glyceryl stearate, cetostearyl alcohol, octyl stearate, methyl isothiazolin-332 
one, methyl-chloro-isothiazolin-one and imidazolidinylurea and water. Caffeine was incorporated at 333 
0.001 % or 0.1 % in the emulsions and 100 mg of formulation was applied to human skin in Franz 334 
cells with an effective area of 0.75 cm2. Perfluoropolymethylisopropylether (1, 3 or 5 % w/w) was 335 
also incorporated in a number of formulations. Steady state flux values of caffeine did not exceed 336 
~1.6 g/cm2/h for the 0.1% caffeine preparations and were ~0.2 g/cm2/ h  for the 0.01 % caffeine 337 
emulsions. The inclusion of the perfluorinated ether had no influence on caffeine penetration.  338 
 Delivery of caffeine from an emulsion compared with an acetone solution was examined by 339 
Chambin-Remoussenard et al. (1993). The O/W emulsion consisted of water, polyoxyethylene glycol 340 
stearate, stearyl alcohol, petroleum and ethanol. Vehicles were applied to the volar forearm of 341 
healthy volunteers with average doses being 2.22 ± 0.14 and 2.37 ±0.10 g/cm2 for the acetone 342 
solution and emulsion respectively. Recovery was measured for up to 6 h post treatment by washing 343 
treated sites and swabbing; following the washing procedure the area was tape stripped to 344 
determine the amounts of caffeine deposited in the skin. Significant differences in amounts 345 
recovered by washing and swabbing were evident for the emulsion (1443 ± 251 ng/cm2) compared 346 
with the acetone solution (995 ± 172 ng/cm2). Results for the tape stripping procedure also 347 
confirmed a five-fold difference in amount of caffeine deposited in skin following application of the 348 
emulsion (212 ng/cm2) versus acetone (37 ng/cm2). Significant lateral spread of caffeine in the SC 349 
away from the treatment site was observed for the acetone solution (~40%) but not for the 350 
emulsion. The results are probably affected by the low surface tension of acetone which will spread 351 
over the skin whilst it evaporates.  352 
 Delivery of caffeine from an O/W and a water-in-oil-in water (W/O/W) emulsion prepared 353 
with similar components and containing caffeine 1% (w/w) was reported by Doucet et al. (1998). The 354 
primary emulsion consisted of Vaseline™ oil, cetearyl octanoate, magnesium sulphate, distilled 355 
water and caffeine with cetyl dimethicone copolyol as the lipophilic emulsifier. For the multiple 356 
(W/O/W/) emulsion the O/W preparation was further mixed with an external aqueous phase 357 
consisting of an ethylene oxide/propylene oxide block copolymer and water. Formulations were 358 
applied to human skin mounted in Franz cells at a dose of 260 11 mg/cm2 and permeation was 359 
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measured over 24 h. Cumulative percentages absorbed were 3.21 ± 0.18% for the O/W emulsion 360 
and 1.25 ± 0.17% for the W/O/W emulsions. Actual flux values were ~6 g/cm2/h for the primary 361 
emulsion and 2.4 g/cm2/h for the multiple emulsion. This may reflect the higher water content in 362 
the double emulsion which will lower the thermodynamic activity of caffeine compared with the 363 
single emulsion. The authors did not comment on the rationale for evaluation of a large excess of 364 
the formulation in the in vitro study.  365 
 Dreher et al. (2002) evaluated in vitro skin permeation of caffeine from O/W and W/O 366 
emulsions as well as from a hydrogel under finite dose conditions. All preparations contained 367 
caffeine 1% w/w. The oil phases for the emulsions were similar and contained silicone oil and 368 
almond oil. For the O/W emulsion sorbitan tristearate and PEG-40 stearate were used as emulgents; 369 
cetyl dimethicone dipolyol and methyl glucose dioleate were used to emulsify the W/O formulation. 370 
The hydrogel consisted of water, ethanol, Carbomer®, triethanolamine, imidazolidinyl urea and 371 
methylparaben. Preparations were applied at a dose of 10 g/cm2 to human skin mounted in Franz 372 
cells and permeation was monitored for 24 h. At the end of the experiment skin was washed and 373 
tape stripped to remove the SC. Epidermis was then separated from the dermis by a heat treatment 374 
and tissues were digested and treated to extract caffeine. The cumulative percentage of caffeine 375 
which permeated was 15-20%. No significant differences were observed between the various 376 
formulations. About 80% of caffeine was recovered from the surface of the skin with 1% extracted 377 
from the epidermis.  378 
 Caffeine delivery from microemulsions, emulsions and hydrogel formulations was studied by 379 
Bolzinger et al. (2007). Microemulsions are composed of water, oils and and surfactants and form 380 
single phase thermodynamically stable systems (Santos et al., 2008). The emulsion and 381 
microemulsion formulations contained the same lipophilic components namely isostearyl 382 
isostearate, cyclomethicone and diisopropyl adipate and the microemulsion also contained PG. 383 
Carbomer® was used to prepare the hydrogel which also contained the same amount of PG as the 384 
microemulsion (2%). For permeation studies 1 g (equivalent to 8 mg of caffeine) of each formulation 385 
was applied to full thickness porcine skin in Franz cells with an effective diffusion area of 2.54 cm2. 386 
Interestingly, skin samples with and without hypodermis were prepared as the authors noted that to 387 
exert lipolytic effects caffeine would need to reach the deeper adipose tissue. Cumulative amounts 388 
of caffeine which permeated were highest for the microemulsion formulation for skin samples 389 
containing hypodermis (~400 g/cm2) and for tissue with no hypodermis (600 g/cm2). Mass balance 390 
studies indicated that the highest amount of caffeine was also delivered to the hypodermis from the 391 
microemulsion formulations. Despite the higher surfactant content in the microemulsion 392 
formulations Trans epidermal water loss (TEWL) measurements indicated that the barrier function of 393 
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skin samples was not compromised following exposure to these formulations. This is the only in vitro 394 
study which actually examines whether caffeine permeates to the proposed target site for cosmetic 395 
effects.   396 
 Solid particles are typically used to stabilise the oil and water interface in Pickering 397 
emulsions and such systems are reported to have more favourable stability characteristics than 398 
emulsions stabilised with emulgents. Frelichowska et al. (2009) investigated Pickering W/O 399 
emulsions for caffeine delivery compared with conventional W/O emulsions. The Pickering 400 
emulsions under investigation were prepared with silica and contained the same lipophilic phase (a 401 
blend of cylomethicones) as the conventional emulsion; caffeine content was 0.8% (w/w) for both 402 
emulsions. Formulations were loaded onto full thickness porcine skin in Franz cells (0.5 g/2.54 cm2). 403 
Cumulative amounts of caffeine which permeated after 24 h were ~500 g/cm2 for the Pickering 404 
emulsion and ~220 g/cm2 for the conventional emulsion. The more favourable penetration from 405 
the Pickering emulsion was suggested to reflect specific interactions of formulation components 406 
and/or particles with the skin. Tape stripping studies indicated the presence of silica particles in the 407 
SC and the authors also demonstrated greater adhesion energy of Pickering systems compared with 408 
the conventional emulsion. The latter was proposed to contribute to the surprisingly higher levels of 409 
permeation observed for these systems which effectively encapsulate the drug.  410 
 The influence of microemulsion structure on the skin permeation of caffeine was evaluated 411 
by Naoui and co-workers (2011). Three types of microemulsions containing caffeine were studied: 412 
O/W, W/O and bicontinuous; an aqueous solution of caffeine was included as a control (Table 5). 413 
Formulations (1 g/2.54 cm2) containing 0.8% (w/w) caffeine were applied to full thickness porcine 414 
skin and permeation was monitored for 24 h. The cumulative permeation at 24 h for the 415 
formulations and the steady state flux values could be ranked as follows: O/W microemulsion > 416 
bicontinuous microemulsion> W/O microemulsion = caffeine solution. Permeation data were 417 
comparable or better than observed for the earlier study which employed the same experimental 418 
conditions (Bolzinger et al., 2007). Importantly, the authors also noted the possible penetration 419 
enhancement effects associated with solubilisation of skin lipids by surfactant components.  420 
 421 
 422 
 423 
 424 
 425 
 426 
 427 
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Table 5. Composition of microemulsions and aqueous solution for caffeine skin delivery studied by 428 
Naoui et al, (2010)  429 
Component O/W 
 
Bicontinuous W/O Aqueous Solution  
Tween® 21 30 27 24 - 
Span® 20 - 3 6 - 
Isononyl isononanoate 35 35 35 - 
Water  35 35 35 100 
 430 
 431 
 432 
 A range of microemulsions (bicontinuous, O/W and W/O) containing caffeine (1% w/w) were 433 
also evaluated by Zhang and Michniak-Kohn (2011). Labrasol®, Cremophor® EL and isopropyl 434 
myristate were used as the oil, surfactant and co-surfactant components of the various systems; 435 
Azone® or bromo-iminosulfurane were also incorporated in some formulations as permeation 436 
enhancers. Microemulsions were applied to dermatomed porcine skin; the volume applied was 150 437 
L but the diffusional area of the Franz cells was not documented. Maximum cumulative amounts 438 
permeated were 240 ug/cm2 for the O/W microemulsion; incorporation of penetration enhancers 439 
did not promote any further enhancement from this formulation.  440 
 Sintov and Greenberg (2014) prepared caffeine microemulsions (1% w/w) using isopropyl 441 
palmitate as the oil phase, Labrasol® and glyceryl oleate as surfactants, propylene carbonate and 442 
varying proportions of water. A microemulsion gel containing caffeine was also prepared by 443 
incorporation of amorphous silica into the formulation containing 20 % water. Formulations (0.5 g) 444 
were applied to full thickness porcine skin (diffusional area 1.767 cm2) which had been freshly 445 
prepared or frozen (-20°C) and an aqueous solution of caffeine was used as the control. The 446 
maximum amount of caffeine permeation at 24 h from the aqueous solution was ~80 g/cm2 for the 447 
freshly prepared tissue. For the W/O liquid emulsion and for the microemulsion gel containing 20% 448 
water the corresponding amounts permeated were 320 g/cm2 and 270 g/cm2. Permeation data 449 
for the frozen tissue was much higher which the authors attributed to storage however this problem 450 
has not been reported previously.  451 
 452 
4.4 Nanoparticles 453 
Nanoparticles prepared with starch derivatives and loaded with caffeine were prepared by 454 
Santander-Ortega et al. (2010). Permeation experiments conducted with human skin indicated <0.2 455 
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g/cm2 of caffeine permeated after 12 h in Franz cells. Surprisingly the authors stated that the data 456 
suggested the potential of these carriers for transdermal delivery. Silica-caffeine nano-composites 457 
were prepared using a ball-milling process by Pilloni and co-workers (2013). Subsequently a gel 458 
formulation containing the nano-composites as well as a control gel formulation were evaluated in 459 
vitro using new-born pig skin. Caffeine loading in both formulations was 3 % (w/w) and formulations 460 
were dosed to skin samples at either 100 or 200 mg to an effective diffusional area of 0.6 cm2. After 461 
8 h permeation the amounts of caffeine permeated were markedly lower for the nano-composite 462 
formulation ( ~100 g and ~180 g) compared with the control formulation (~500 g and 600 g). 463 
Washing and mass balance studies suggested that most of the drug in the nano-composite 464 
formulation had remained on the surface of the skin.  465 
 Puglia et al. (2014) prepared solid lipid nanoparticles (SLN) loaded with caffeine(SLN-CAF) by 466 
solvent emulsification and dispersion. The SLN-CAF dispersion was then loaded into a xanthan gel 467 
formulation and evaluated alongside a reference gel containing the same amount of caffeine. Franz 468 
cell studies were carried out with heat-separated human epidermis for 24 h. Approximately 8 g of 469 
caffeine had permeated from the SLN-CAF gel at the end of the permeation study compared with ~3 470 
g from the reference gel. As the precise loading of each formulation in the cells was not provided, it 471 
is difficult to determine whether the SLN-CAF formulation is advantageous compared with other 472 
approaches.  473 
 The results for all chemical enhancement approaches assessed in vitro are summarised in 474 
Table 6 along with values for permeation parameters, where reported. As different concentrations 475 
are reported by different research groups caution should be exercised when comparing results for 476 
different studies. Typically, high amounts of caffeine permeation are associated with infinite dose 477 
conditions; only a limited number of studies have been conducted with finite dose application.  478 
 479 
5. Physical enhancement methods 480 
5.1 Mechanical pressure 481 
Treffel and co-workers (1993) investigated the effects of pressure on caffeine permeation in 482 
vitro. Caffeine solutions were applied (50 l of an acetone solution, 320 g/ml or 15 mg/ml) to 483 
human skin samples mounted in Franz cells with an effective diffusion area of 3.14 cm2. Following 484 
evaporation of the acetone pressure was applied using an air pump for 30 min to achieve an 485 
increase of 0.25 bar in atmospheric pressure. At the end of the 24 h permeation experiment tissue 486 
integrity was evaluated by application of methylene blue to the skin samples. No significant increase 487 
in caffeine permeation with increased pressure was observed for the lower dose however a 1.8 fold 488 
increase (p<0.05) in caffeine cumulative absorption was achieved for the higher dose. Actual 489 
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cumulative amounts of caffeine permeated were 9.4 ± 2.2 g/cm2 for the control and 17.0 ± 3.4 490 
g/cm2 for the experiments conducted with application of increased pressure. The authors 491 
suggested that the higher permeation might reflect increased filling of the SC under pressure and/or 492 
a greater role for trans-appendageal transport.  493 
 494 
5.2 Ultrasound 495 
 The application of ultrasound or sonophoresis to enhance skin permeation of caffeine was 496 
reported by Mitragotri et al. (1994). Heat separated human skin was mounted in diffusion cells 497 
which were modified to accommodate an ultrasound transducer. Experiments were conducted at 498 
room temperature and a thermocouple was used to monitor any variation in temperature over the 499 
course of the experiment. Radiolabelled caffeine was applied in the donor compartment (total 500 
volume 8.0 mL) at a concentration of 1 Ci/mL in PBS to an effective diffusion area of 3.14 cm2. An 501 
ultrasound generator was used to apply continuous ultrasound at frequencies of 1 or 3 MHz with 502 
intensities up to 2 W/cm2. Tissue resistance was monitored at regular intervals before, during and 503 
after ultrasound treatment. Only modest improvements in caffeine permeation (1.2 fold 504 
enhancement) were reported compared with the control. This may reflect the temperature rise 505 
which was observed after the initial application of ultrasound. Continuous and pulsed ultrasound 506 
was used to promote caffeine delivery in human skin in vitro by Boucaud et al. (2001). A solution of 507 
radiolabelled caffeine (5 Ci/mL) was applied to the donor compartment at a dose of 3 mL/3.14 cm2. 508 
Ultrasound was applied at a frequency of 20 Hz and an intensity of 2.5 W/m2. Although the amount 509 
of caffeine which permeated after 8 h increased for both continuous (~35 ng/cm2) and pulsed (~25 510 
ng/cm2) treatments compared with the control (~10 ng/cm2), a temperature increase was also 511 
associated with the ultrasound application.  512 
An in vivo study using pigs was conducted to investigate the influence of ultrasound on 513 
caffeine permeation and skin morphology by Pires-de-Campos et al. (2008). Five treatment sites 514 
were delineated on shaved dorsal areas of the animals. Treatments were as follows: placebo gel, gel 515 
containing caffeine (5 % w/w), gel and ulstrasound, gel containing caffeine and ultrasound. 516 
Continuous ultrasound was used for 1 min/cm2 at a frequency of 3 MHz and an intensity of 0.2 517 
W/cm2. Histological processing confirmed that sites treated with ultrasound and caffeine were 518 
thinner than other treatment sites; a reduction in the number of adipocytes was also claimed 519 
however caffeine content of the tissue was not determined.  520 
 521 
5.3 Iontophoresis 522 
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 Iontophoresis as an approach to enhance skin penetration of caffeine has been studied by 523 
Marra and colleagues (2008). A device which combined a low voltage to generate a constant current 524 
along with pulses of high-frequency electro-porating voltage was employed. A simple gel was 525 
prepared containing water, PG and a gelling agent; a second gel containing caffeine and a number of 526 
other components was then added to this base gel. This was then applied to porcine ear skin 527 
mounted in vertical diffusion cells. A set of silver/silver chloride electrodes in the receptor chamber 528 
completed the electrical circuit and the current was monitored throughout the experiment. The 529 
intensity setting applied was 6 V and frequency and duration of voltage pulses was 1724 Hz and 160 530 
sec respectively. The total electro-treatment time was 20 min and passive permeation was also 531 
investigated as a control. Significantly greater (p<0.05) amounts of caffeine were determined in 532 
tissue for electro-treatment compared with passive diffusion for 20 min. No significant differences in 533 
tissue levels of caffeine were observed for electro-treatment for 20 min followed by 60 min passive 534 
diffusion compared with 80 min passive diffusion.  535 
 536 
5.4 Microneedles 537 
 Donnelly and co-workers have pioneered the development and application of drug loaded 538 
dissolving microneedles (MNs) for topical and transdermal drug delivery (Donnelly et al., 2008; 539 
Migalska et al., 2011). MNs prepared from blends of poly (methyl vinyl ether co maleic acid) were 540 
loaded with caffeine (3.1 mg) and evaluated following application to dermatomed (300 -350 m) 541 
and full thickness (700 -750 m) neonatal porcine skin in Franz cells (2012). Control patches loaded 542 
with caffeine but without MNs were also investigated for comparison. After 24 h the cumulative 543 
amounts of caffeine which permeated from the control and MN patches were respectively 136.4 ± 544 
23.2 g and 1833.8 ± 302.3 g for dermatomed skin and 81.4 ± 15.2 g and 1408.6 ± 133.7 g for 545 
full thickness skin. Optical coherence tomography indicated that MN penetrated into the skin to a 546 
depth of 430 m creating a conduit or pore of ~220 m.  547 
 548 
6. 6. Summary and conclusions  549 
Considerable efforts have been made in recent decades and are still ongoing to promote dermal 550 
delivery of caffeine. The literature evaluated reports studies conducted with relatively simple 551 
vehicles as well as more complex preparations. Of the various passive formulation strategies to 552 
promote percutaneous penetration of caffeine which have been reviewed, the greatest effort has 553 
centred on either conventional emulsions or microemulsions. A problem with many of these studies 554 
is the use of infinite dose conditions which over-estimate the penetration enhancement which will 555 
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be achieved for more realistic finite dose application conditions. Although some commercial 556 
cosmetic patch formulations are available which likely do contain infinite does of caffeine, data on 557 
their efficacy and delivery characteristics are lacking. Overall, the results for the various permeation 558 
studies suggest that a large percentage of the applied caffeine resides on the skin surface. In order 559 
to optimise formulations in the future it will be necessary to identify strategies which address this 560 
problem. The caffeine needs to remain in solution in order to permeate, the caffeine needs to be at 561 
a high thermodynamic activity and also not crystallise in the SC once it has partitioned into the skin 562 
lipids.  Until recently transdermal delivery of caffeine has only been feasible for premature infants 563 
because of their compromised skin barrier. The advent of MNs has expanded the possibilities for 564 
systemic delivery of caffeine. Caffeine has a long history as a model hydrophilic compound thus the 565 
data collated here should have relevance for other molecules with similar physicochemical 566 
properties.  567 
 568 
569 
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